Member Info for Moneymunch

Q2....Gl :-)

26/5/21

SHP2 inhibitors are an up-and-coming class of medicine that has drawn the attention of Big Pharma. Novartis has three pipeline projects in the works for a SHP2 inhibitor called TNO155 in solid tumors. Sanofi, meanwhile has nabbed the rights to Revolution Medicines' similar molecule they call RMC-4630 for $50 million upfront and $500 million in potential milestones.

Research conducted by Revolution has shown that SHP2 appears to play a role in cancer growth in up to 45% of non-small cell lung cancers, as well as colorectal and ovarian cancers and melanoma.

https://www.fiercebiotech.com/biotech/nikang-snags-200m-series-c-and-stacks-its-board-following-january-licensing-erasca
...................................
21/1/21

Lead candidate SFX-01 inhibits SHP2, a protein associated with a number of different cancer types

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces preclinical data demonstrating that SFX-01 is an inhibitor of SHP2.

SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-receptor protein tyrosine phosphatase that is associated with breast cancer, leukaemia, lung cancer, liver cancer, gastric cancer, laryngeal cancer, oral cancer and other cancer types.

In-vitro and in-vivo data generated by Professor Philip Eaton, Queen Mary University of London, demonstrates that SFX-01 modifies SHP2, inhibiting its phosphatase activity; this phosphatase is implicated in many aspects of cancer . SHP2 is involved in several cancer-related processes, including cancer cell invasion and metastasis, apoptosis, DNA damage, cell proliferation, cell cycle and drug resistance. SHP2 may therefore be a therapeutic target of great potential.

This exciting data provides another pathway through which SFX-01 may be a valuable anti-cancer agent in addition to its effects on the STAT3 pathway, thought to be the principal mechanism of action in metastatic breast cancer.

Further preclinical work is being conducted in cancer models and data will be announced in due course.

https://www.lse.co.uk/news/EVG/in-brief-evgen-pharma-notes-positive-preclinical-data-for-sfx-01-rgs6vzk8w2zwyh8.html

Positive efficacy data from Prof Chalmers will be a complete game changer for all concerned and very likely see SFX-01 as prime candidate, and then super-charged acceleration for Boris's home pill Autumn target....Gla ;-)))

All good things......fingers firmly crossed that our time has come.....Gla ;-)

Looking good, this could explode on positive efficacy data and then prime candidate for Boris's home pill target. Gla :-)

11/3/21

Following this positive step, the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in-patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during Q2 of the calendar year 2021.

Completion of recruitment to the STAR trial is anticipated at the end of 2021/early 2022, assuming there are no substantial changes in the total patients to be recruited.

Prior to the recent £11m fund raise, Evgen's business model was to seek non-dilutive funding to advance their pipeline towards commercial JV partnerships, and so no doubt Evgen was always hoping for outside funding for the Covid/ARDS trial. SFX-01 was selected from over 130 drug candidates by LifeArc and University of Dundee and so it's definitely no shot in the dark. The eagerley awaited interim efficacy data is the assessment of the first 100 unblinded patients, and if positive would see the trial will continue as planned , but could also be dramatically accelerated if deemed to have home pill potential......news must be very close imho....Gl ;-)

Roll on Monday, the chart looks primed for some stellar news imho...Gla holders. ;-)

Reata's pipeline isn't that much more advanced than Evgen's, especially if we get confirmation of positive efficacy data on the Star-Covid phase 2/3 patient trial, yet Evgen's market cap is only £21M compare to Reata's $4B and Barclays target of $6.5B!!! Gla ;-)

21/5/21

Barclays (LON:BARC) analyst Carter Gould maintained a Buy rating on Reata Pharmaceuticals (NASDAQ:RETA) on Thursday, setting a price target of $180, which is approximately 61.29% above the present share price of $111.6.

The company's market cap is $4.05 billion.

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

https://www.investing.com/news/barclays-stick-to-their-buy-rating-for-reata-pharmaceuticals-2513735

Interim efficacy assessment data imminent, and potentially encouraging with study results still expected later this year!!!???? ;-)

Tayside Clinical Trials Unit
@TASC_TCTU
Replying to
@TASC_TCTU

We were also heavily involved with non-UPH COVID study STAR-COVID19 also led by @ProfJDChalmers
in @NHSTayside

We hope the results of both of these studies will be available later this year. #ICTD2021
3:55 PM · May 20, 2021·Twitter Web App

...............

Tayside Clinical Trials Unit
@TASC_TCTU
·
5m
TCTU was proud to be involved in the only multi-centre UPH COVID trial led from Scotland, STOP-COVID19 led by @ProfJDChalmers
and @NHSTayside

Home pill target....supercharged patient trial acceleration??? Gla :-)))

Tayside Clinical Trials Unit

@TASC_TCTU

·

55m

As part of novel trial design, TCTU is building on our incredibly successful relationship with community pharmacies, ensuring wider inclusion and participation in clinical research. Several new studies will be opening up over coming months, taking research into the community.

James D Chalmers Retweeted

Tayside Clinical Trials Unit

@TASC_TCTU

·

2h

Happy International Clinical Trials Day! To celebrate we will tweet out some of our activities over the past year across the day. #ICTD2021

We just need the thumbs UP from Prof Chalmers.....and then it'll be Boom time.....tomorrow would be good. Gla :-)

Good news fast approaching......i reckon....Gla ;-)

News.....imminent??? Gla ;-)

A great reminder parker....the multi-billion dollar Chinese Raybow, bought PharmAgra in 2019, who Evgen have world exclusive rights to SFX-01 and its analogues, and Raybow have just invested $15m ( 22/3/21) to expand PharmAgra manufacturing capacity in the US.....all bodes well. Gl :-)

hTtps://www.prnewswire.co.uk/news-releases/raybow-pharmaceutical-announces-u-s-expansion-801052071.html

A risk/reward firmly in our favour imho....although no guarantees of course, but a complete game if Prof Chlamers reports positive efficacy data which would very likely see SFX-01 as prime candidate for Boris's home pill target and perhaps he's already put a forward order in for a 100 million doses or so.....can you imagine??? Gla ;-))))

Evgen Pharma plc, of Cheshire, U.K., said a preprint publication from Johns Hopkins University demonstrates that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by several variants of the SARS-CoV-2 virus and another coronavirus. Data showed that the inhibition of SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are pretreated with sulforaphane and when sulforaphane is administered 24 hours after viral inoculation. The work also shows that sulforaphane acts synergistically with the antiviral drug remdesivir (Gilead Sciences Inc.). The authors further established that the effects of sulforaphane, administered orally, were observed in vivo in a mouse model infected with the SARS-CoV-2 virus, where reduction in both viral load and lung pathology were observed.

Lol bobsson, we'll all know soon enough when Huw UPdates the market on Prof Chalmers efficacy assessment, and hope this time around " the "rocket is about to leave the launch pad ", although the train will do............Gl ;-)))

Perfectly poised for news imho ( good or bad )....although the chart almost looks like a carbon copy of SNG's last year which was on the slide, just before their stellar rise.....Tick Tock .....C'mon Prof Chalmers, Huw and Co....time's UP...next week please!!! ;-)))

A very interesting research project announced today by University of Dundee on their focus on the roll of of neutrophils and the harmful inflammation effects of Covid-19, which must add weight to SFX-01's anti-inflammatory properties and interestingly enough "Neutrophil functional studies in isolated cells" are part of the Exploratory objectives of SFX-01 Covid/Ards trial at University of Dundee, and so the timing could be viewed as encouraging??? Gla :-)

https://www.dundee.ac.uk/stories/project-investigate-blood-vessel-damage-covid-19-patients

and Prof Chalmers is still looking to expand his department which could also be viewd as an encouraging sign. ;-)

James D Chalmers
@ProfJDChalmers
·
10 May
Just two days left to apply for our technician post
Who wouldn't want to work on epithelial biology in lung disease?

Come and join us!

https://jobs.dundee.ac.uk/fe/tpl_uod01.a

An opportunity has arisen for a research technician to support our internationally leading Lung Infection laboratory at the University of Dundee. The group studies a range of lung infections including COPD, bronchiectasis and COVID-19.

You will be expected to provide high quality technical assistance to Professor Chalmers, Dr Shoemark and the other members of the research team. Core tasks will include processing biological samples, culture of airway epithelial cells at air liquid interface, cell culture experiments, microscopy and generation of experimental data using methods such as ELISA.

You will support the principal investigators, post-docs and PhD students as part of a multidisciplinary team, performing laboratory research to a high standard, organising study data and supervising undergraduates. You will work collaboratively with team members to support multiple ongoing research studies with a focus on the role of motile cilia in chronic lung disease.